Summer 2024
Software Engineering Intern
Summer 2024
Posted on 11/8/2023
PostEra
11-50 employees
AI-powered medicinal chemistry for drug discovery
No salary listed
Remote
 AI & Machine Learning |
|---|
 DevOps & Infrastructure |
|---|
 Software Engineering |
|---|
- Experience in software development outside of the classroom
- Interest in building production-grade software used by chemists and biologists
- Accelerate Medicinal Chemistry using machine learning
- Advance small molecule programs through partnerships with biopharma
- Advance internal pipeline
- Raise funds from investors
- Close AI partnerships
- Launch and lead open-science drug discovery efforts
- Experience in Python development
- Strong statistical and quantitative skills
- Comfort with modern development and deployment tools (Git, Linux, AWS, Docker)
- Application of machine learning to scientific problems
- Academic or professional experience with organic chemistry
- Familiarity with the RDKit library
PostEra.ai speeds up medicinal chemistry by applying machine learning to design and plan synthesis for drug candidates, accelerating the Design-Make-Test cycle in drug discovery. Its AI tools propose molecular designs and viable synthesis routes to help researchers optimize properties and iterate experiments faster. It generates revenue mainly through large partnerships and collaborations with pharma companies and government programs, such as a Pfizer AI Lab deal and NIH antiviral collaboration. The goal is to shorten time and reduce cost in drug discovery by leveraging AI-assisted chemistry and sustained industry collaborations.
Company Size
11-50
Company Stage
Series A
Total Funding
$24.1M
Headquarters
Santa Clara, California
Founded
2019
Your Connections
People at PostEra who can refer or advise you
Simplify's Take
What believers are saying
- Pfizer's January 2025 expansion adds ADC payload optimization and small-molecule programs.
- NIH-funded antiviral discovery provides non-dilutive capital and pandemic-preparedness visibility.
- Internal fertility and PCOS programs create optionality beyond partner revenue.
What critics are saying
- Revenue concentrates in Pfizer and Amgen, exposing PostEra to partner budget cuts.
- PostEra lacks disclosed late-stage assets, leaving it dependent on future discovery milestones.
- Pfizer can internalize validated workflows, pressuring PostEra's pricing and renewal leverage.
What makes PostEra unique
- PostEra's Proton combines generative chemistry with synthesis-aware medicinal chemistry.
- Pfizer expanded collaboration to $610M on January 7, 2025.
- PostEra also closed over $1B in AI drug discovery partnerships.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Stock Options
Professional Development Budget
Conference Attendance Budget
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 2%PostEra is building a modern biopharma, using machine learning to accelerate medicinal chemistry, to develop cures for diseases, faster.
Optibrium, a leading developer of software and AI for small molecule discovery, and PostEra, an AI-first biotechnology company with advanced machine learning (ML) technology for preclinical discovery, today announced a collaboration to integrate Optibrium’s StarDrop platform with PostEra’s Manifold software.
BOSTON, May 19, 2022 /PRNewswire/ -- PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH funding
What You Should Know: PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients. PostEra will use the proceeds to advance a series of partnered drug discovery programs, initiate its own internal drug discovery, and ... Read More
PostEra, a biotechnology company specialising in machine learning for drug discovery, today announced that it has received a grant of £100,000 from the independent medical charity LifeArc to support an international effort to rapidly develop a potential antiviral candidate for COVID-19.